Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023
November 02, 2023 at 08:07 am EDT
Share
Omnicell, Inc. provided revenue guidance for the fourth quarter and full year of 2023. For the quarter, company expects total revenues to be between $247 million and $267 million. The Company expects fourth quarter 2023 product revenues to be between $142 million and $152 million, and fourth quarter 2023 service revenues to be between $105 million and $115 million.
For the year, company expects total revenues to be between $1.135 billion and $1.155 billion. The Company expects full year 2023 product revenues to be between $705 million and $715 million, and full year 2023 service revenues to be between $430 million and $440 million. The Company expects full year 2023 technical services revenues to be between $222 million and $227 million.
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.